Benitec Biopharma (NASDAQ:BNTC) Shares Cross Below Fifty Day Moving Average of $2.22

Benitec Biopharma Inc. (NASDAQ:BNTC – Get Rating) shares crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $2.22 and traded as low as $1.95. Benitec Biopharma shares last traded at $1.96, with a volume of 8,487 shares traded.

Separately, HC Wainwright began coverage on Benitec Biopharma in a report on Thursday, February 17th. They issued a “buy” rating and a $10.00 target price for the company.

The firm has a market capitalization of $16.02 million, a P/E ratio of -0.01 and a beta of 1.44. The stock has a 50-day moving average of $2.22 and a 200 day moving average of $2.77. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.11 and a current ratio of 5.11.

Benitec Biopharma (NASDAQ:BNTC – Get Rating) last released its quarterly earnings results on Monday, February 14th. The biotechnology company reported ($117.99) EPS for the quarter. The company had revenue of $0.03 million during the quarter. On average, equities analysts predict that Benitec Biopharma Inc. will post -2.08 EPS for the current year.

A hedge fund recently raised its stake in Benitec Biopharma stock. Morgan Stanley increased its holdings in shares of Benitec Biopharma Inc. (NASDAQ:BNTC – Get Rating) by 549.0% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 84,725 shares of the biotechnology company’s stock after acquiring an additional 71,671 shares during the period. Morgan Stanley owned about 1.76% of Benitec Biopharma worth $438,000 at the end of the most recent quarter. 20.15% of the stock is owned by hedge funds and other institutional investors.

Benitec Biopharma Company Profile (NASDAQ:BNTC)

Benitec Biopharma Inc, a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection.

Recommended Stories